LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **linagliptin** (DPP-4 inhibitors)
- Comparator (class): **canagliflozin** (SGLT2 Inhibitors)
- Outcome: **Thyroid tumor**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	127,176	105,483	123	1.17
Merative CCAE	4,793	3,523	6	1.70
Merative MDCD	2,654	1,818	<5	<2.75
Merative MDCR	1,490	1,474	<5	<3.39
Optum Clinformatics	11,462	9,164	16	1.75
Optum EHR	5,438	1,138	<5	<4.39
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **linagliptin** (DPP-4 inhibitors)
- Comparator (class): **glyburide** (Sulfonylureas)
- Outcome: **Renal cancer**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	-	-	-	-
Merative CCAE	5,630	3,838	9	2.35
Merative MDCD	2,750	1,873	<5	<2.67
Merative MDCR	1,020	932	<5	<5.36
Optum Clinformatics	12,298	9,870	19	1.93
Optum EHR	6,425	1,263	<5	<3.96
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **saxagliptin** (DPP-4 inhibitors)
- Comparator (class): **glyburide** (Sulfonylureas)
- Outcome: **Bladder cancer**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	1,157	1,343	0	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	46,122	35,861	42	1.17
Merative CCAE	0	0	0	-
Merative MDCD	-	-	-	-
Merative MDCR	1,451	1,368	<5	<3.65
Optum Clinformatics	6,476	5,714	5	0.87
Optum EHR	5,291	1,880	<5	<2.66
Veterans Affairs	0	0	0	-

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **sitagliptin** (DPP-4 inhibitors)
- Comparator (class): **exenatide** (GLP-1 Receptor Agonists)
- Outcome: **Venous thromboembolic events**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	645,122	578,578	2,800	4.84
Merative CCAE	79,894	67,847	316	4.66
Merative MDCD	8,550	6,125	75	12.25
Merative MDCR	13,924	13,431	168	12.51
Optum Clinformatics	41,599	33,677	337	10.01
Optum EHR	65,870	30,162	240	7.96
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **sitagliptin** (DPP-4 inhibitors)
- Comparator (class): **semaglutide** (GLP-1 Receptor Agonists)
- Outcome: **Genitourinary infection**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	211,683	158,911	4,323	27.20
Merative CCAE	7,317	4,488	182	40.55
Merative MDCD	-	-	-	-
Merative MDCR	1,946	1,013	73	72.08
Optum Clinformatics	4,113	2,314	154	66.56
Optum EHR	21,879	9,972	410	41.11
Veterans Affairs	54	17	0	0.00

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **dulaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **dapagliflozin** (SGLT2 Inhibitors)
- Outcome: **Acute pancreatitis**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	159,923	125,129	187	1.49
Merative CCAE	11,162	9,150	16	1.75
Merative MDCD	2,549	1,456	10	6.87
Merative MDCR	1,127	747	<5	<6.69
Optum Clinformatics	12,066	8,213	29	3.53
Optum EHR	13,963	6,975	18	2.58
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **exenatide** (GLP-1 Receptor Agonists)
- Comparator (class): **dapagliflozin** (SGLT2 Inhibitors)
- Outcome: **Bladder cancer**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	36,976	20,736	14	0.68
Merative CCAE	3,060	1,726	<5	<2.90
Merative MDCD	534	276	0	0.00
Merative MDCR	186	88	0	0.00
Optum Clinformatics	1,383	891	0	0.00
Optum EHR	2,993	1,249	0	0.00
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **exenatide** (GLP-1 Receptor Agonists)
- Comparator (class): **glyburide** (Sulfonylureas)
- Outcome: **Acute renal failure**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	0	0	0	-
Merative CCAE	8,646	4,737	18	3.80
Merative MDCD	910	451	10	22.16
Merative MDCR	818	519	5	9.63
Optum Clinformatics	4,400	2,499	22	8.80
Optum EHR	4,484	1,791	29	16.19
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **glimepiride** (Sulfonylureas)
- Outcome: **Venous thromboembolic events**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	118,206	95,874	360	3.75
Merative CCAE	9,690	7,791	23	2.95
Merative MDCD	1,662	1,033	9	8.71
Merative MDCR	1,083	846	6	7.09
Optum Clinformatics	7,389	5,531	37	6.69
Optum EHR	9,946	2,757	29	10.52
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **glipizide** (Sulfonylureas)
- Outcome: **Renal cancer**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	268,889	200,340	108	0.54
Merative CCAE	17,862	13,533	8	0.59
Merative MDCD	2,861	1,550	<5	<3.23
Merative MDCR	1,995	1,160	5	4.31
Optum Clinformatics	22,677	16,085	17	1.06
Optum EHR	19,553	9,066	6	0.66
Veterans Affairs	19,646	17,631	19	1.08

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)